Intralesional interferon-alpha-2b for the treatment of Peyronie's disease

International Journal of Impotence Research

Volumn 14, Issue 5, 2002, Pages 336-339

  Lacy, G L ^a   Adams, D M ^a   Hellstrom, W J G ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Interferon alpha 2b; Intralesional; Non surgical therapy; Peyronie's disease

Indexed keywords

ALPHA2B INTERFERON; COLLAGEN; COLLAGENASE; PLACEBO; PROSTAGLANDIN E;

ANOREXIA; CLINICAL FEATURE; CLINICAL TRIAL; COLOR ULTRASOUND FLOWMETRY; DRUG EFFECT; DRUG ERUPTION; DRUG MECHANISM; ERECTILE DYSFUNCTION; FLU LIKE SYNDROME; HEART ARRHYTHMIA; HUMAN; HYPOTENSION; MALE; PENILE FIBROSIS; PEYRONIE DISEASE; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

HUMANS; INJECTIONS, INTRALESIONAL; INTERFERON ALFA-2B; MALE; PENILE INDURATION; TREATMENT OUTCOME;

EID: 0036805139     PISSN: 09559930     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ijir.3900867     Document Type: Review

References (32)

1. Carson CC. Francoix Gigot de la Peyronie. Invest Urol 1981; 19: 62-63.
2. Levine LA. Peyronie's disease: A difficult sexual dysfunction problem. West J Med 1998; 169: 168-169.
3. Gelbard MK, Dorey F, James K. The natural history of Peyronie's disease. J Urol 1990; 144: 1376-1379.
4. Carson CC. Peyronie's disease: Medical and surgical management. In: Hellstrom WJG, ed. Handbook of Sexual Dysfunction. American Society of Andrology: San Francisco; 1999; pp 93-98.
5. Scardino PL, Scott WW. The use of tocopherols in the treatment of Peyronie's disease. Ann NY Acad Sci 1949; 52: 390-401.
6. Yudkin JS. Peyronie's disease in association with metoprolol. Lancet 1977; 2: 1355.
7. Van de Berg JS et al. Mechanisms in calcification in Peyronie's disease. J Urol 1982; 127: 52-56.
8. Somers KD, Winters PA, Dawson DM. Chromosomal abnormalities in Peyronie's disease. J Urol 1987; 137: 672-676.
9. Jarow JP, Lowe FC. Penile trauma: An etiologic factor in Peyronie's disease and erectile dysfunction. J Urol 1997; 158: 1388-1390.
10. Levine LA. Treatment of Peyronie's disease with intralesional verapamil injection. J Urol 1997; 158: 1395-1399.
11. Chilton CP, Castle WM, Westwood CA, Pryor JP. Factors associated in the etiology of Peyronie's disease. Br J Urol 1982; 54: 748-750.
12. Nyberg LM, Bias WB, Hochberg MC, Walsh PC. Identification of an inherited form of Peyronie's disease with autosomal dominant inheritance and association with Dupuytren's contracture and histocompatibility B7 cross-reacting antigens. J Urol 1982; 128: 48-51.
13. Hellstrom WJG, Bivalacqua TJ. Peyronie's disease: Etiology, medical, and surgical therapy. J Androl 2000; 21: 347-354.
14. Roddy TR, Goldstein I, Devine CJ. Peyronie's disease, part I. Am Urol Assoc Update Ser 1991; 10: 1.
15. Hacshe-Klunder R. Treatment of Peyronie's disease using para-aminobenzoate potassium (Potaba), para-aminobenzoic acid potassium. Urologe 1978; 17: 224-227.
16. Ralph DJ, Brooks MD, Botazzi GF. The treatment of Peyronie's disease with tamoxifen. Br J Urol 1992; 70: 648-661.
17. Akkus E et al. Is colchicine effective in Peyronie's disease? A pilot study. Urology 1994; 44: 291-295.
18. Gelbard MK, Lindner A, Kaufman JJ. The use of collagenase in the treatment of Peyronie's disease. J Urol 1985; 134: 280-283.
19. Gelbard MK, James K, Riach P, Dorey F. Collagenase versus placebo in the treatment of Peyronie's disease: A double-blind study. J Urol 1993; 149: 56-58.
20. Levine LA, Merrick PE, Lee RC. Intralesional verapamil injection for the treatment of Peyronie's disease. J Urol 1994; 151: 1522-1524.
21. Rehman J, Benet A, Melman A. Use of intralesional verapamil to dissolve Peyronie's disease plaque: A long-term single-blind study. Urology 1998, 51: 620-626.
22. Stuart-Harris RG, Lauchler R. The clinical application of the interferons: A review. Med J Aust 1992; 156: 869-872.
23. Duncan MR, Berman B, Nseyo UO. Regulation of the proliferation and biosynthetic activities of cultured human Peyronie's disease fibroblasts by interferons-alpha, -beta, and gamma. Scand J Urol Nephrol 1991; 25: 89-94.
24. Ahuja SK, Sikka SC, Hellstrom WJG. Stimulation of collagen production in an in vitro model for Peyronie's disease. Int J Impot Res 1999; 11: 207-212.
25. Berman B, Duncan MR. Short-term keloid treatment in vivo with human interferon alpha 2b results in a selective and persistent normalization of keloid fibroblast collagen glycosa-minoglycan, and collagenase production in vitro. J Am Acad Dermatol 1989; 21: 694-702.
26. Benson RC, Knoll LD, Furlow WL. Interferon-alpha-2b in the treatment of Peyronie's disease. J Urol 1991; 145: 342A.
27. Wegner HE, Andersen R, Knipsel HH, Miller K. Treatment of Peyronie's disease with local interferon-alpha-2b. Eur Urol 1995; 28: 236-240.
28. Wegner HE, Andersen R, Knipsel HH, Miller K. Local interferon-alpha-2b is not an effective treatment in early stage Peyronie's disease. Eur Urol 1997; 32: 190-193.
29. Judge IS, Widniewski ZS. Intralesional interferon in the treatment of Peyronie's disease: A pilot study. Br J Urol 1997; 79: 40-42.
30. Ahuja S et al. A pilot study demonstrating clinical benefit from intralesional interferon-alpha-2b in the treatment of Peyronie's disease. J Androl 1999; 20: 444-448.
31. Brake M, Loertzer H, Horsch R, Keller H. Treatment of Peyronie's disease with local interferon-alpha-2b. Br J Urol 2001; 87: 654-657.
32. Novak TE et al. Combined intralesional interferon alpha 2B and oral vitamin E in the treatment of Peyronie's disease. J LA State Med Soc 2001; 153: 358-363.